Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways

Fig. 6

AZD4547 and crizotinib synergistically inhibited activation of MAPK/ERK pathway in G03 xenograft derived GC cells. GC cells derived from G03 xenograft were treated with 200nM/L crizotinib or 30nM/L AZD4547, either alone or as a combo treatment(Cri + AZD) for 1 hour. Whole cell lysates were collected and analyzed by western blot. Cell lysates were immunoblotted for phospho- and total protein as indicated

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us